Historical salary details - Mr. Mark T. Iwicki, Director and Chief Executive Officer, Inhibikase Therapeutics Inc
Mr. Mark T. Iwicki is the Director and Chief Executive Officer of Inhibikase Therapeutics Inc. They also hold 1 other positions in and Kala Pharmaceuticals Inc.
Mr. Mark T. Iwicki
Director and Chief Executive Officer
-
Gross Remuneration
-
Current Company
Inhibikase Therapeutics Inc
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2025 | Inhibikase Therapeutics Inc | Director and Chief Executive Officer | - | - |
| 2025 | Kala Pharmaceuticals Inc | Chairman of the Board | - | - |
| 2024 | Q32 Bio Inc. | Chairman of the Board | - | - |
| 2024 | Akero Therapeutics Inc | Chairman of the Board | - | - |
| 2024 | Merus N.V | Independent Director | - | - |
| 2023 | Akero Therapeutics Inc | Chairman of the Board | 606.1 K | 270.1 % |
| 2023 | Merus N.V | Independent Director | 311.1 K | 4.8 % |
| 2023 | Aerovate Therapeutics Inc | Chairman of the Board | 218.3 K | 18.5 % |
| 2023 | Third Harmonic Bio Inc | - | 174.6 K | -60.5 % |
| 2023 | Kala Pharmaceuticals Inc | Chairman of the Board and Chief Executive Officer | - | - |
| 2022 | Third Harmonic Bio Inc | Chairman of the Board | 441.5 K | 1323.1 % |
| 2022 | Merus N.V | Independent Director | 296.8 K | 77.9 % |
| 2022 | Aerovate Therapeutics Inc | Chairman of the Board | 184.3 K | -68.1 % |
| 2022 | Akero Therapeutics Inc | Chairman of the Board | 163.7 K | -44.0 % |
| 2022 | Kala Pharmaceuticals Inc | Chairman of the Board and Chief Executive Officer | - | - |
| 2021 | Aerovate Therapeutics Inc | Chairman of the Board | 577.8 K | - |
| 2021 | Akero Therapeutics Inc | Chairman of the Board | 292.3 K | 0.4 % |
| 2021 | Merus N.V | Independent Director | 166.8 K | -2.1 % |
| 2021 | Pulmatrix Inc | - | 41.7 K | -44.9 % |
| 2021 | Third Harmonic Bio Inc | Chairman of the Board | 31.0 K | - |
| 2021 | Pulmatrix Inc | Independent Director | - | - |
| 2021 | Kala Pharmaceuticals Inc | Chairman of the Board and Chief Executive Officer | - | - |
| 2020 | Akero Therapeutics Inc | Chairman of the Board | 291.0 K | -30.4 % |
| 2020 | Merus N.V | Independent Director | 170.4 K | 38.2 % |
| 2020 | Pulmatrix Inc | Independent Director | 75.7 K | -3.6 % |
| 2020 | Aerovate Therapeutics Inc | Chairman of the Board | - | - |
| 2020 | Kala Pharmaceuticals Inc | Chairman of the Board, President and Chief Executi | - | - |
| 2019 | Akero Therapeutics Inc | Chairman of the Board | 418.0 K | 463.3 % |
| 2019 | Merus N.V | Independent Director | 123.3 K | 7.6 % |
| 2019 | Pulmatrix Inc | Chairman of the Board | 78.5 K | -33.2 % |
| 2019 | Kala Pharmaceuticals Inc | Chairman of the Board, President and Chief Executi | - | - |
| 2018 | Pulmatrix Inc | Chairman of the Board | 117.6 K | 55.0 % |
| 2018 | Merus N.V | Independent Director | 114.5 K | - |
| 2018 | Akero Therapeutics Inc | Chairman of the Board | 74.2 K | - |
| 2018 | Kala Pharmaceuticals Inc | President, Chief Executive Officer and Chairman of | - | - |
| 2017 | Pulmatrix Inc | Chairman of the Board | 75.9 K | 18.0 % |
| 2017 | Merus N.V | Chairman of the Board | - | - |
| 2017 | Kala Pharmaceuticals Inc | President, Chief Executive Officer and Chairman of | - | - |
| 2016 | Pulmatrix Inc | Chairman of the Board | 64.3 K | -75.5 % |
| 2016 | Merus N.V | Chairman of the Supervisory Board | - | - |
| 2016 | Kala Pharmaceuticals Inc | Chief Executive Officer and Chairman of the Board | - | - |
| 2015 | Pulmatrix Inc | Chairman of the Board | 262.2 K | - |
| 2015 | Merus N.V | Chairman of the Supervisory Board | - | - |